About iSTAR Medical
iSTAR Medical has exclusive rights to the STAR® biomaterial from the University of Washington in Seattle (USA) for ophthalmic use. The porous material exhibits outstanding anti-fibrotic and anti-inflammatory properties providing the foundation for the development of MINIjectTM, designed to be a best-in-class micro-invasive glaucoma surgery (MIGS) device. MIGS is the most promising and fastest-growing therapeutic option for the treatment of glaucoma. The fast-growing glaucoma surgical device market is expected to reach $1.84 bn worldwide by 2025.*
iSTAR Medical’s management team and board have a successful track record in end-to-end product development, with proven clinical, regulatory and market access capabilities. The company is backed by specialised institutional and private investors.
* Glaucoma Surgical Device Market Report, Market Scope 2020